As a result, it will be available only on private prescription at a cost of €215 or more a month. That equates to an annual ...

While this condition can be caused by diabetes, tissue disease and neurological disorders, which damage the nerves and blood ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

At medical conferences and hospital cafeterias, one thing has become increasingly clear—many doctors are using Ozempic, ...

We recently compiled a list of the 13 Best Dividend Growth Stocks With 10%+ Yearly Increases. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

Analysts have deemed LLY stock a “Strong Buy,” with an average target price of $984.29, indicating an upside potential of 12.1% from Friday’s closing price. Among the 24 analysts covering the stock, ...

Global Diabetes Drug Market growth is driven by the rising incidence of diabetes and increasing adoption of innovative treatment solutions.Austin, United States, Feb. 10, 2025 (GLOBE NEWSWIRE) -- ...

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...